SCHEMBL5723342

SCHEMBL5723342

O=[N+]([O-])c1ccc(S(=O)(=O)NCC2CC2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 1/20 0.63
CYP19A1 P11511 1/20 0.57
CA1 P00915 4/20 0.56
CA2 P00918 4/20 0.56
MMP1 P03956 1/20 0.53
MMP2 P08253 1/20 0.53
MMP9 P14780 1/20 0.53
MMP8 P22894 1/20 0.53
MMP13 P45452 1/20 0.53
CA12 O43570 1/20 0.53
CA3 P07451 1/20 0.53
CA4 P22748 1/20 0.53
CA6 P23280 1/20 0.53
CA5A P35218 1/20 0.53
CA7 P43166 1/20 0.53
CA9 Q16790 1/20 0.53
CA13 Q8N1Q1 1/20 0.53
CA14 Q9ULX7 1/20 0.53
CA5B Q9Y2D0 1/20 0.53
KMT2A Q03164 4/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21465270 0.90 HTR2C (0.53) GBA1CYP19A1CA1CA2MMP1
SCHEMBL16054033 0.90 PKM (0.57) GBA1CYP19A1CA1CA2MMP1
SCHEMBL27479521 0.85 ALDH1A1 (0.52) GBA1CYP19A1CA1CA2KMT2A
SCHEMBL25185019 0.84 CYP19A1 (0.44) GBA1CYP19A1CA1CA2MMP1
SCHEMBL5036093 0.84 KMT2A (0.69) GBA1CYP19A1CA1CA2MMP1
SCHEMBL9058761 0.81 CYP19A1 (0.51) CYP19A1CA1CA2MMP1MMP2
SCHEMBL4766369 0.81 CYP19A1 (0.51) CYP19A1CA1CA2MMP1MMP2
SCHEMBL7526085 0.79 CA2 (0.63) CYP19A1CA1CA2MMP1MMP2
SCHEMBL3012277 0.78 GBA1 (0.69) GBA1CYP19A1CA1CA2CA9
SCHEMBL2376303 0.78 GBA1 (0.69) GBA1CA1CA2CA12CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1406876-B1 2-ANILINO-PYRIMIDINE DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS ASTRAZENECA AB (SE) 2006-12-27 EP disclosed
US-6939872-B2 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors ASTRAZENECA AB (SE) 2005-09-06 US disclosed
US-20040198757-A1 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors ASTRAZENECA AB (SE) 2004-10-07 US disclosed
EP-1406876-A1 2-ANILINO-PYRIMIDINE DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS Astrazeneca AB (SE) 2004-04-14 EP disclosed
EP-0614898-B1 INDOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL USE THEREOF TORAY INDUSTRIES (JP) 2003-05-07 EP disclosed
WO-2002096887-A1 2-ANILINO-PYRIMIDINE DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS ASTRAZENECA AB (SE) 2002-12-05 WO disclosed
US-6291470-B1 DELTA-OPIOID ANTAGONIST HAVING HIGH SELECTIVITY AND ACTIVITY, THAT EXHIBITS IMMUNOSUPPRESSIVE ACTION, ANTIALLERGIC ACTION, ANTI-INFLAMMATORY ACTION AND BRAIN CELL-PROTECTING ACTION TORAY INDUSTRIES, INC. (JP) 2001-09-18 US disclosed
US-6087369-A AN IMMUNOSUPPRESSIVE AGENT, ANTIALLERGIC AGENT, ANTI-INFLAMMATORY AGENT AND BRAIN CELL-PROTECTING AGENT TORAY INDUSTRIES, LTD. (JP) 2000-07-11 US disclosed
CN-1043766-C Indole derivative and preparation and pharmaceutical using of same TORAY INDUSTRIES (JP) 1999-06-23 CN disclosed
US-5852030-A Indole derivatives, process for producing the same and medicinal uses of the same TORAY INDUSTRIES, INC. (JP) 1998-12-22 US disclosed
CN-1092425-A Indole derivatives, its manufacture method and medicinal use thereof TORAY INDUSTRIES (JP) 1994-09-21 CN disclosed
EP-0614898-A1 INDOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL USE THEREOF TORAY INDUSTRIES, INC. (JP) 1994-09-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198757-A1 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors CCNT1, CCNI, CDK2 GBA1 4137/4885CYP19A1 1178/4885CA1 2019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.